NCT05509933PHASE3Recruiting

Budesonide Prophylaxis for Engraftment Syndrome After Hematopoietic Cell Transplantation

Henry Ford Health System

Start Date

11/9/2022

Completion Date

12/30/2027

Summary

The purpose of this study is to determine if budesonide prophylaxis starting day 5 after transplant reduces engraftment fever in autologous and allogeneic stem cell transplant recipients.

Eligibility Criteria

Age Range: 18 years to 80 years

Inclusion Criteria: * • Patients 18-80 years of age with a diagnosis of a hematological malignancy * Meet the BMT program criteria to undergo hematopoietic stem cell transplantation for hematologi malignancies Exclusion Criteria: * • Patients enrolled in investigational clinical trials * Sct for non hematologic malignancies

Interventions

DRUG

Budesonide

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Engraftment Syndrome

Locations

Henry Ford Health System

Detroit, Michigan 48202

United States